Mechanism of disease
gMG subtypes vary based on the specific autoantibodies involved, influencing disease severity and response to treatment. IgG autoantibodies cause disrupted neuromuscular communications and result in muscle weakness, a primary symptom of gMG.2 Types of IgG antibodies in gMG can include:
FcRn is a protein that plays a crucial role in regulating IgG antibody levels in the body. By recycling IgG, FcRn helps maintain antibody levels in the bloodstream.1
However, in autoimmune diseases like gMG, this function can inadvertently sustain pathogenic antibodies that drive disease activity.1
An FcRn blocker is a targeted therapy that disrupts the IgG recycling process. By blocking FcRn, this type of treatment reduces circulating IgG, specifically lowering IgG, including pathogenic antibodies that contribute to symptoms in gMG.1
FcRn=neonatal fragment crystallizable receptor;
gMG=generalized myasthenia gravis;
IgG=immunoglobulin G.
